Article title: Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia
Authors: Michael L. Ganz, Ameya Chavan, Rahul Dhanda, Michael Serbin and Charles Yonan
Journal: Journal of Medical Economics
Bibliometrics: Volume 24, Number 1, pages 103–113
DOI: https://doi.org/10.1080/13696998.2020.1867443
Dear Editor,
We have become aware of a computational error in our model to evaluate the cost-effectiveness of valbenazine and deutetrabenazine for the treatment of tardive dyskinesia, which resulted in an inaccurate rendition of the cost-effectiveness acceptability curves (CEACs) for these compounds as had been shown in . It is important to note that the interpretation of the CEACs as presented in our manuscript – i.e. that “compared with valbenazine, deutetrabenazine is generally not a cost-effective option at any willingness to pay threshold ≤$300,000” – continues to remain valid. Nonetheless, we regret the error and append a corrected version of .
Figure 4. Cost-effectiveness acceptability curves for valbenazine and deutetrabenazine. Abbreviations. DTBZ, deutetrabenazine; QALY, quality-adjusted life year; VBZ, valbenazine.
